Fate Therapeutics Inc Net Income per Employee (FATE), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Fate Therapeutics Inc   (NASDAQ: FATE)
 

Fate Therapeutics Inc Net Income per Employee

FATE's Quarterly Results, Trends, Rankings, Statistics
Fate Therapeutics Inc recorded a cumulative net loss of $-126 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 65 other companies achieving higher income per employee. While Fate Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3598 to 3648.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FATE Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -782,584 -806,876 -846,677 -969,528 -1,065,354
FATE's Total Ranking # 3648 # 3598 # 2539 # 2589 # 3105
Seq. Net Income Change - - - - -

FATE Company Profile >> Back to FATE Efficiency Comparisons >> Compare FATE Net Income per Employee to its Competitors

FATE Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 66
Healthcare Sector # 546
Overall Market # 3648

Net Income per Employee Statistics
High Average Low
$ -129,776 $ -719,425 $ -1,825,957
(Dec 31 2013)   (Sep 30 2022)




  News about Fate Therapeutics Inc Income per employee

Fate Therapeutics Raises $100 Million to Elevate Patient Care with iPSC-derived Cellular Immunotherapies.

Fate Therapeutics Raises $100 Million in Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, has successfully priced its underwritten offering of 14,545,454 shares of common stock at $5.50 per share. The offering includes participation from both new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital, and a renowned life-sciences focused investor.
The announcement of this offering highlights Fate Therapeutics commitment to advancing its robust pipeline of innovative iPSC-derived cellular immunotherapies for patients battling cancer and autoimmune disorders. By leveraging the power of induced pluripotent stem cells, the company aims to develop transformative treatments that have the potential to revolutionize the field of medicine and significantly improve patient outcomes.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-03T11:45:04+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.